Covidien Announces Health Canada Approval for its Generic Myocardial Perfusion Imaging Kit | Covidien
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Healthcare Company News Covidien Covidien Announces Health Canada Approval for its Generic Myocardial Perfusion Imaging Kit

Covidien Announces Health Canada Approval for its Generic Myocardial Perfusion Imaging Kit

Company News - Covidien

Health Canada has approved the Covidien ANDS for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection.

Covidien (NYSE: COV), a leading global provider of healthcare products, announced that Health Canada has approved the Company’s Abbreviated New Drug Submission (ANDS) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien’s generic product is fully substitutable for Cardiolite, a myocardial perfusion imaging agent used for detecting coronary artery disease.

With Health Canada approval of the ANDS, which was filed by the Company’s Canadian subsidiary, Covidien’s generic product is expected to be available for customers in Canada this summer. The Company’s generic product also is available in the U.S., the U.K., Denmark, Germany and Puerto Rico.

“We are pleased to receive approval in Canada and to introduce this generic diagnostic option to meet patients’ needs,” said Timothy R. Wright, President, Pharmaceutical Products and Imaging Solutions, Covidien.

Covidien’s Imaging Solutions business is a leading provider of radiopharmaceuticals used in nuclear medicine imaging procedures. It also supplies contrast media delivery systems, which combine contrast media and power injectors, for Computed Tomography ( CT ), X-ray and Magnetic Resonance Imaging ( MRI ) procedures.

ABOUT Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments:Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2008 revenue of nearly $10 billion, Covidien has more than 41,000 employees worldwide in 59 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

Source: Covidien